Ablynx is a Belgian biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments. Today, the Company has approximately 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease.
Type
Public
HQ
Gent, BE
Founded
2001
Size (employees)
344 (est)
Website
ablynx.com
Ablynx was founded in 2001 and is headquartered in Gent, BE

Key People at Ablynx

William Jenkins

William Jenkins

Team Member
Russell Greig

Russell Greig

Team Member
Bo Jesper Hansen

Bo Jesper Hansen

Team Member
Peter Fellner

Peter Fellner

Chairman of the Board
Frank Landolt

Frank Landolt

IP and legal counsel
Guido Gielen

Guido Gielen

VP Human Resources

Ablynx Office Locations

Ablynx has an office in Gent
Gent, BE (HQ)
21 Technologiepark-Zwijnaarde

Ablynx Data and Metrics

Ablynx Financial Metrics

EUR

Market capitalization (16-Nov-2016)

584.9 b

Closing share price (16-Nov-2016)

9.6
Ablynx's current market capitalization is €584.9 b.
Show all financial metrics

Ablynx Market Value History

Traffic Overview of Ablynx

Ablynx Online and Social Media Presence

Ablynx Company Life and Culture

You may also be interested in